SPONSOR
Tyra Biosciences, Inc
Total Trials
4
Recruiting
4
Phases
Phase 1, Phase 2
Conditions studied: Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, AdultFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationAdvanced Solid TumorsFGFR4 Gene MutationFGFR4 Gene Fusions
Tyra Biosciences, Inc is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Tyra Biosciences, Inc
How many clinical trials has Tyra Biosciences, Inc sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Tyra Biosciences, Inc, of which 4 are actively recruiting participants. These trials cover conditions including Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Tyra Biosciences, Inc research focus on?
Tyra Biosciences, Inc clinical trials span Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, and additional conditions. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Tyra Biosciences, Inc clinical trial?
To participate in a Tyra Biosciences, Inc trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tyra Biosciences, Inc trials with current recruitment status updated daily.
Clinical Trials by Tyra Biosciences, Inc
NCT06915753 Phase 1
Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Metastatic Hepatocellular Carcinoma
NCT07265947 Phase 2
Recruiting
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Low Grade Upper Tract Urothelial Carcinoma
NCT06995677 Phase 2
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBC
NCT06842355 Phase 2
Recruiting
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Achondroplasia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology